Acetylator genotype and arylamine-induced carcinogenesis

Area of Science:

• Toxicology
• Genetics
• Carcinogenesis

Background:

• Arylamine chemicals from various sources are carcinogenic, requiring metabolic activation by host enzymes.
• Genetic regulation of these metabolic pathways influences tumor incidence across tissues, species, and individuals.
• Acetylation polymorphism plays a key role in arylamine metabolism, affecting both activation and deactivation processes.

Purpose of the Study:

• To explore the role of acetylation polymorphism in arylamine-induced carcinogenesis.
• To investigate the toxicological significance of O-acetylation of N-hydroxyarylamine carcinogens.
• To examine associations between acetylator phenotype and tumor incidence in various organs.

Main Methods:

• Enzymological and genetic investigations of acetyltransferase enzymes.
• Studies in animal models characterized for acetylation polymorphism.
• Epidemiological investigations correlating acetylator phenotype with tumor incidence.

Main Results:

• Acetylation polymorphism influences both activation and deactivation pathways in arylamine metabolism.
• O-acetylation of N-hydroxyarylamine carcinogens is genetically coregulated with N-acetylation.
• Associations observed between acetylator phenotype and tumors of the urinary bladder, colon, and larynx.

Conclusions:

• Acetylation polymorphism is significant in arylamine carcinogenesis, affecting tumor risk differently across organs.
• Further characterization of extrahepatic acetyltransferases is needed.
• New methodologies will enhance understanding of acetylator status in carcinogenesis.